Compare IRIX & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRIX | MRKR |
|---|---|---|
| Founded | 1989 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2M | 23.0M |
| IPO Year | 1996 | 2010 |
| Metric | IRIX | MRKR |
|---|---|---|
| Price | $0.99 | $1.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.25 |
| AVG Volume (30 Days) | 48.7K | ★ 116.3K |
| Earning Date | 03-26-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.47 | ★ 33.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,593,000.00 | N/A |
| Revenue This Year | $10.43 | N/A |
| Revenue Next Year | $7.32 | $621.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.79 | $0.81 |
| 52 Week High | $1.65 | $4.07 |
| Indicator | IRIX | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 23.19 | 37.52 |
| Support Level | $0.87 | $0.83 |
| Resistance Level | $1.22 | $1.44 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 8.43 | 17.86 |
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.